Visual impairment, retinopathy and maculopathy in patients with sickle cell disease Eye Diseases
Conditions
Interventions
People with sickle cell disease attending their haematology clinic will be informed about the study by their clinical team. They will be provided with the participant information sheet detailing the s
Sponsors
London North West Healthcare NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Willingness to participate 2. Ability to provide informed consent 3. Age 16 years or older 4. Diagnosis of SCD of any genotype
Exclusion criteria
Exclusion criteria: 1. Inability to consent 2. Poor image quality 3. Age <16 years 4. Sickle cell trait only
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The prevalence of visual impairment due to sickle cell retinopathy or maculopathy: best corrected visual acuity LogMAR =0.3 in at least one eye measured through best corrected visual acuity test at baseline visit | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The prevalence of each stage of sickle cell retinopathy and maculopathy and correlation with: 1.1. Number of hospital admissions with acute sickle cell episodes in the past 12 months 1.2. Serum HbF level 1.3. Serum Hb level Collection into source document of the number of hospital admissions in the past 12 months and serum HbF and Hb level results within 3 months of study entry at baseline visit 2. The impact of sickle cell retinopathy and maculopathy on vision-related quality of life measured using the NEI-VFQ 25 questionnaire at baseline visit 3. The acceptability to patients of retinal imaging and routine screening for sickle cell retinopathy and maculopathy measured using acceptability questionnaire at baseline visit | — |
Countries
England, United Kingdom
Contacts
Public ContactLara Barcella
Outcome results
None listed